Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
The purpose of this study is to assess the safety and effectiveness of nivolumab immunotherapy alone and with the drug cabozantinib to reduce the chance that mucosal melanoma will come back after surgery. Nivolumab boosts the power of the immune system to detect and destroy cancer cells. Cabozantinib inhibits cancer cell growth by blocking certain enzymes.
The current standard treatment for throat cancer that is positive for the human papillomavirus (HPV) is 7 weeks of daily radiation therapy given together with chemotherapy, but this treatment can have severe side effects. In this study, researchers are assessing significantly lower doses of radiation (3 weeks) to achieve local and regional control of the tumor with significantly fewer side effects. Treatments will be given in combination with lower doses of chemotherapy (cisplatin, carboplatin, and 5-fluorouracil) as well in people with HPV-positive throat cancer.
Researchers want to see how well reparixin works against myelofibrosis. This disease is a rare bone marrow cancer that disrupts your body's normal blood cell production. 
